Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells
Open Access
- 11 March 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 98 (6), 1076-1084
- https://doi.org/10.1038/sj.bjc.6604278
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Lapatinib Antitumor Activity Is Not Dependent upon Phosphatase and Tensin Homologue Deleted on Chromosome 10 in ErbB2-Overexpressing Breast CancersCancer Research, 2007
- Targeting Tyrosine Kinases in Cancer: The Second WaveScience, 2006
- HER-2 Is an Independent Prognostic Factor in Endometrial Cancer: Association With Outcome in a Large Cohort of Surgically Staged PatientsJournal of Clinical Oncology, 2006
- Complex networks orchestrate epithelial–mesenchymal transitionsNature Reviews Molecular Cell Biology, 2006
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- Expression of androgen receptor and 5α‐reductases in the human normal endometrium and its disordersInternational Journal of Cancer, 2002
- Establishment of new epithelial carcinoma cell lines by blocking monolayer formationZeitschrift für Krebsforschung und Klinische Onkologie, 1997
- Establishment and Characterization of Human Cell Lines from a Serous Papillary Adenocarcinoma of the EndometriumGynecologic Oncology, 1994
- Growth factors and steroid hormone action in endometrial cancerThe Journal of Steroid Biochemistry and Molecular Biology, 1994
- Significance of epidermal growth factor receptor expression in primary human endometrial cancerInternational Journal of Cancer, 1994